Differences in major leukocyte subsets per μL blood between patients with hematological neoplasia and healthy controls
| Population . | Healthy control∗ (n = 87) . | Lymphoid neoplasms∗ (n = 41) . | P value healthy vs lymphoid neoplasms† . | Myeloid neoplasms∗ (n = 86) . | P value healthy vs myeloid neoplasms† . |
|---|---|---|---|---|---|
| Myeloid cells | 3424 (2737; 4775) | 3461 (2680; 4286) | .7 | 4056 (2429; 6338) | .5 |
| Neutrophils | 2789 (2215; 3947) | 2771 (2167; 3707) | .8 | 3190 (1868; 5324) | .6 |
| Eosinophils | 83 (46; 151) | 72 (35; 102) | .2 | 68 (35; 165) | .4 |
| Monocyten | 412 (323; 612) | 417 (343; 538) | 1 | 404 (295; 633) | .9 |
| Lymphocytes | 2529 (2073; 3189) | 1556 (1150; 2536) | < .001 | 2031 (1462; 2864) | .002 |
| B cells | 304 (206; 462) | 160 (47; 542) | .03 | 251 (122; 384) | .03 |
| T cells | 1937 (1513; 2390) | 1220 (752; 1675) | < .001 | 1520 (993; 2150) | .002 |
| CD4+ T cells | 939 (643; 1293) | 421 (258; 694) | < .001 | 577 (355; 928) | < .001 |
| Naive CD4+ T cells | 398 (232; 641) | 100 (36; 194) | < .001 | 194 (88; 389) | < .001 |
| CM CD4+ T cells | 330 (218; 491) | 184 (115; 306) | .001 | 224 (141; 346) | .001 |
| EM CD4+ T cells | 89 (58; 144) | 77 (40; 116) | .06 | 55 (34; 88) | .002 |
| TE CD4+ T cells | 7 (3; 20) | 2 (2; 10) | .02 | 3 (2; 11) | .009 |
| CD8+ T cells | 444 (277; 581) | 380 (258; 532) | .4 | 284 (178; 443) | .001 |
| Naive CD8+ T cells | 106 (49; 164) | 35 (18; 111) | .002 | 53 (23; 103) | .002 |
| CM CD8+ T cells | 43 (23; 68) | 31 (17; 59) | .2 | 28 (15; 55) | .01 |
| EM CD8+ T cells | 89 (47; 173) | 95 (61; 150) | .7 | 57 (33; 118) | .02 |
| TE CD8+ T cells | 132 (50; 203) | 116 (72; 212) | .6 | 100 (33; 168) | .1 |
| NK cells | 293 (182; 425) | 209 (103; 292) | .003 | 231 (122; 355) | .04 |
| Population . | Healthy control∗ (n = 87) . | Lymphoid neoplasms∗ (n = 41) . | P value healthy vs lymphoid neoplasms† . | Myeloid neoplasms∗ (n = 86) . | P value healthy vs myeloid neoplasms† . |
|---|---|---|---|---|---|
| Myeloid cells | 3424 (2737; 4775) | 3461 (2680; 4286) | .7 | 4056 (2429; 6338) | .5 |
| Neutrophils | 2789 (2215; 3947) | 2771 (2167; 3707) | .8 | 3190 (1868; 5324) | .6 |
| Eosinophils | 83 (46; 151) | 72 (35; 102) | .2 | 68 (35; 165) | .4 |
| Monocyten | 412 (323; 612) | 417 (343; 538) | 1 | 404 (295; 633) | .9 |
| Lymphocytes | 2529 (2073; 3189) | 1556 (1150; 2536) | < .001 | 2031 (1462; 2864) | .002 |
| B cells | 304 (206; 462) | 160 (47; 542) | .03 | 251 (122; 384) | .03 |
| T cells | 1937 (1513; 2390) | 1220 (752; 1675) | < .001 | 1520 (993; 2150) | .002 |
| CD4+ T cells | 939 (643; 1293) | 421 (258; 694) | < .001 | 577 (355; 928) | < .001 |
| Naive CD4+ T cells | 398 (232; 641) | 100 (36; 194) | < .001 | 194 (88; 389) | < .001 |
| CM CD4+ T cells | 330 (218; 491) | 184 (115; 306) | .001 | 224 (141; 346) | .001 |
| EM CD4+ T cells | 89 (58; 144) | 77 (40; 116) | .06 | 55 (34; 88) | .002 |
| TE CD4+ T cells | 7 (3; 20) | 2 (2; 10) | .02 | 3 (2; 11) | .009 |
| CD8+ T cells | 444 (277; 581) | 380 (258; 532) | .4 | 284 (178; 443) | .001 |
| Naive CD8+ T cells | 106 (49; 164) | 35 (18; 111) | .002 | 53 (23; 103) | .002 |
| CM CD8+ T cells | 43 (23; 68) | 31 (17; 59) | .2 | 28 (15; 55) | .01 |
| EM CD8+ T cells | 89 (47; 173) | 95 (61; 150) | .7 | 57 (33; 118) | .02 |
| TE CD8+ T cells | 132 (50; 203) | 116 (72; 212) | .6 | 100 (33; 168) | .1 |
| NK cells | 293 (182; 425) | 209 (103; 292) | .003 | 231 (122; 355) | .04 |
CM, central memory cells (CD45RA−CCR7+); EM, effector memory cells (CD45RA−CCR7−); TE, terminal effector cells (CD45RA+CCR7−).
Significant (<0.05) P values are highlighted in bold.
Median (Q1 and Q3); n (%); T-cell maturation parameters (CCR7, CD45RA) could not be assessed in 1 healthy control, 3 patients with lymphoid, and 1 patient with myeloid neoplasia because of technical reasons.
P values calculated using Dunn post hoc test.